Back
Puma Biotechnology Quote, Financials, Valuation and Earnings
This trade could move overnight Thursday!
Access my free presentation on these overnight trades right here
Sell
41
PBYI
Puma Biotechnology
Last Price:
5.03
Seasonality Move:
6.87%
7 Day Trial
ALL ACCESS PASS
$
7
The little-known AI stock you need to read about now...
Get the name - FREE.Puma Biotechnology Price Quote
$5.03
+0.15 (+3.07%)
(Updated: April 26, 2024 at 6:55 PM ET)
Puma Biotechnology Key Stats
Sell
41
Puma Biotechnology (PBYI)
is a Sell
Day range:
$4.72 - $5.06
52-week range:
$2.13 - $7.73
Dividend yield:
0%
P/E ratio:
10.84
P/S ratio:
0.98
P/B ratio:
4.4%
Volume:
231.2K
Avg. volume:
470K
1-year change:
79.41%
Market cap:
$235.3M
Revenue:
$235.6M
EPS:
$0.45
How Much Does Puma Biotechnology Make?
-
How Much Are Puma Biotechnology's Sales Annually?
PBYI Revenues are $235.6M -
How Much Profit Does Puma Biotechnology's Make A Year?
PBYI net income is $21.6M
Is Puma Biotechnology Growing As A Company?
-
What Is Puma Biotechnology's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.1% -
What Is Puma Biotechnology's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Puma Biotechnology Stock Price Performance
-
Did Puma Biotechnology Stock Go Up Last Month?
Puma Biotechnology share price went down by -12.7% last month -
Did PBYI's Share Price Rise Over The Last Year?
PBYI share price rose by 79.41% over the past 1 year
What Is Puma Biotechnology 52-Week High & Low?
-
What Is Puma Biotechnology’s 52-Week High Share Price?
Puma Biotechnology has traded as high as $7.73 over the past 52 weeks -
What Is Puma Biotechnology’s 52-Week Low Share Price?
Puma Biotechnology has traded as low as $2.13 over the past 52 weeks
Puma Biotechnology Price To Free Cash Flow
-
Is Puma Biotechnology Stock Overvalued?
Puma Biotechnology is trading at a price to free cash flow ratio of 16.15 -
Is Puma Biotechnology Stock Undervalued?
Puma Biotechnology EV to Free Cash Flow ratio is 16.63 -
What Is Puma Biotechnology’s Price Earnings Growth Ratio?
PBYI PEG ratio is 0.00 -
Is Puma Biotechnology Trading At A Premium To Earnings?
Puma Biotechnology EV to EBIT ratio is 6.64
Is It Risky To Buy Puma Biotechnology?
-
How Much Debt Does Puma Biotechnology Have?
Total long term debt quarterly is $99.7M -
How Much Cash Does Puma Biotechnology Have?
Cash and short term investments quarterly total is $95.9M -
What Is Puma Biotechnology’s Book Value Per Share?
Book value per share is 1.12
Is Puma Biotechnology Cash Flow Positive?
-
What Is PBYI Cash Flow From Operations?
Cash flow from operations (TTM) is $27M -
What Is Puma Biotechnology’s Cash Flow From Financing?
Cash flow from financing (TTM) is $0 -
What Is Puma Biotechnology’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$19.1M
Puma Biotechnology Return On Invested Capital
-
Is Management Doing A Good Job?
PBYI return on invested capital is 16.24% -
What Is Puma Biotechnology Return On Assets?
ROA measures how assets are converting to revenues and is 10.25% -
What Is PBYI Return On Equity?
ROE is a measure of profitability and is 63.49%
Puma Biotechnology Earnings Date & Stock Price
-
What Is Puma Biotechnology's Stock Price Today?
A single share of PBYI can be purchased today for 4.88 -
What Is Puma Biotechnology’s Stock Symbol?
Puma Biotechnology trades on the nasdaq under the ticker symbol: PBYI -
When Is Puma Biotechnology’s Next Earnings Date?
The next quarterly earnings date for Puma Biotechnology is scheduled on May 2, 2024 -
When Is PBYI's next ex-dividend date?
Puma Biotechnology's next ex-dividend date is April 27, 2024 -
How To Buy Puma Biotechnology Stock?
You can buy Puma Biotechnology shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Puma Biotechnology Competitors
-
Who Are Puma Biotechnology's Competitors?
Below is a list of companies who compete with Puma Biotechnology or are related in some way:
Puma Biotechnology Dividend Yield
Data Unavailable
Puma Biotechnology Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -15.07% |
| Revenue: | 9.9% | -1.84% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 4.33 |
| Downside from Last Price: | -11.2% |